Provided by Tiger Trade Technology Pte. Ltd.

Lantheus

76.43
-1.5600-2.00%
Post-market: 76.17-0.2600-0.34%19:57 EDT
Volume:1.89M
Turnover:144.53M
Market Cap:4.94B
PE:22.41
High:78.01
Open:77.94
Low:75.54
Close:77.99
52wk High:108.91
52wk Low:47.25
Shares:64.61M
Float Shares:59.94M
Volume Ratio:2.13
T/O Rate:3.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.41
EPS(LYR):3.41
ROE:21.45%
ROA:9.27%
PB:4.53
PE(LYR):22.41

Loading ...

Lantheus Holdings posts third quarter revenue of $384.0 million

Reuters
·
Nov 06, 2025

Lantheus CEO Brian Markison to Retire as Board Launches Search for Successor

Reuters
·
Nov 06, 2025

Lantheus Holdings Q3 Free Cash Flow USD 94.7 Million

THOMSON REUTERS
·
Nov 06, 2025

Lantheus Holdings Outlook FY Revenue USD 1,490-1,510 Million

THOMSON REUTERS
·
Nov 06, 2025

Lantheus Holdings Q3 Adjusted EPS USD 1.27 VS. Ibes Estimate USD 1.27

THOMSON REUTERS
·
Nov 06, 2025

Lantheus Holdings Inc - Mary Anne Heino Appointed Executive Chairperson Effective Nov 7, 2025

THOMSON REUTERS
·
Nov 06, 2025

Lantheus Holdings Inc - Mary Anne Heino Will Lead Company as Interim CEO

THOMSON REUTERS
·
Nov 06, 2025

Lantheus Holdings Inc - Brian Markison to Retire as Chief Executive Officer; Board Conducting Search for Next CEO

THOMSON REUTERS
·
Nov 06, 2025

Press Release: Lantheus Announces Leadership Transition Plan

Dow Jones
·
Nov 06, 2025

Lantheus Holdings Faces Investor Class Action Over Securities Fraud Allegations

Reuters
·
Nov 01, 2025

LNTH Lawsuit Alert! Class Action Against Lantheus Holdings

TIPRANKS
·
Oct 30, 2025

Lantheus Holdings Inc - FDA Sets Pdufa Target Action Date for March 29, 2026

THOMSON REUTERS
·
Oct 30, 2025

Lantheus Announces FDA Grants Pdufa Date for Lnth-2501 (Ga 68 Edotreotide), a Pet Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (Sstr+) Neuroendocrine Tumors (Nets)

THOMSON REUTERS
·
Oct 30, 2025

Lantheus Announces FDA Grants PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

GlobeNewswire
·
Oct 30, 2025

BRIEF-Lantheus Announces FDA Acceptance of New Drug Application for MK-6240

Reuters
·
Oct 28, 2025

FDA Accepts Lantheus NDA for MK-6240 Tau PET Imaging Agent in Alzheimer’s Disease

Reuters
·
Oct 28, 2025

Lantheus Announces FDA Acceptance of New Drug Application for Mk-6240, a Pet Imaging Agent Targeting Tau in Alzheimer’s Disease

THOMSON REUTERS
·
Oct 28, 2025

Lantheus Holdings Inc - FDA Sets Pdufa Target Date for August 13, 2026

THOMSON REUTERS
·
Oct 28, 2025

Lantheus Holdings Faces Investor Class Action Over Securities Fraud Allegations

Reuters
·
Oct 28, 2025

Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time

GlobeNewswire
·
Oct 23, 2025